Literature DB >> 26023150

Genome sequence and comparative virulence of raccoonpox virus: the first North American poxvirus sequence.

Clare Fleischauer1, Chris Upton1, Joseph Victoria2, Gwendolyn J B Jones3, Rachel L Roper3.   

Abstract

We report here the complete genome sequence of raccoonpox virus (RCNV), a naturally occurring North American poxvirus. This is the first such North American sequence to the best of our knowledge, and the data showed that RCNV forms a new phylogenetic branch between orthopoxviruses and Yoka poxvirus. RCNV shared overall similarity in genome organization with orthopoxviruses, and the proteins in the central conserved region shared approximately 90  % amino acid identity with orthopoxviruses. RCNV proteins shared approximately 81  % amino acid identity with Yokapox virus proteins. RCNV is missing 10 genes normally conserved in orthopoxviruses, most of which are implicated in virulence. These gene deletions may explain the attenuated phenotype of RCNV in mammals. RCNV contained one unique genome region containing approximately 1 kb of DNA sequence that is not present in any reported poxvirus. It contained a unique ORF predicted to encode a protein with a transmembrane domain. RCNV replicates well in mammalian cells, is naturally attenuated and has been shown to be effective as a vaccine vector platform, so we further tested its safety. We showed here that RCNV is substantially more attenuated than even the highly attenuated VACV-A35Del mutant virus in pregnant, nude and severe combined immunodeficient (SCID) mouse models. RCNV was much safer in pregnant mice and was cleared rapidly from tissues, even in immunocompromised animals, whereas the VACV-A35Del mutant retains virulence and persists in tissues. Thus, RCNV is expected to be a superior vaccine vector for infectious diseases and cancer due to its excellent safety profile, reported vaccine efficacy and ability to replicate in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26023150     DOI: 10.1099/vir.0.000202

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Oncolytic properties of non-vaccinia poxviruses.

Authors:  Marine Ricordel; Johann Foloppe; Christelle Pichon; Annie Findeli; Caroline Tosch; Pascale Cordier; Sandrine Cochin; Eric Quémeneur; Christelle Camus-Bouclainville; Stéphane Bertagnoli; Philippe Erbs
Journal:  Oncotarget       Date:  2018-11-13

2.  The genomes of three North American orthopoxviruses.

Authors:  Chad Smithson; Nick Tang; Scott Sammons; Mike Frace; Dhwani Batra; Yu Li; Ginny L Emerson; Darin S Carroll; Chris Upton
Journal:  Virus Genes       Date:  2016-09-09       Impact factor: 2.198

3.  Protection of bats (Eptesicus fuscus) against rabies following topical or oronasal exposure to a recombinant raccoon poxvirus vaccine.

Authors:  Ben Stading; James A Ellison; William C Carson; Panayampalli Subbian Satheshkumar; Tonie E Rocke; Jorge E Osorio
Journal:  PLoS Negl Trop Dis       Date:  2017-10-04

Review 4.  Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?

Authors:  Malachy I Okeke; Arinze S Okoli; Diana Diaz; Collins Offor; Taiwo G Oludotun; Morten Tryland; Thomas Bøhn; Ugo Moens
Journal:  Viruses       Date:  2017-10-29       Impact factor: 5.048

5.  Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.

Authors:  Michael White; Andrew Freistaedter; Gwendolyn J B Jones; Emmanuel Zervos; Rachel L Roper
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

6.  Genome of Alaskapox Virus, A Novel Orthopoxvirus Isolated from Alaska.

Authors:  Crystal M Gigante; Jinxin Gao; Shiyuyun Tang; Andrea M McCollum; Kimberly Wilkins; Mary G Reynolds; Whitni Davidson; Joseph McLaughlin; Victoria A Olson; Yu Li
Journal:  Viruses       Date:  2019-08-01       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.